EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma

Erika Soga, Go Noguchi iD, Kota Kobayashi, Rio Shibata, Ryosuke Jikuya iD, Tomoyuki Tatenuma, Mitsuru Komeya iD, Hiroki Ito iD, Hisashi Hasumi, Kazuhide Makiyama

IJU Case Reports · 2026-07 · 9 (4)

DOI: 10.1002/iju5.70203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 29.05.2026. Verfasst von Erika Soga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Yokohama City University Graduate School of Medicine Yokohama Kanagawa Japan. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lenvatinib plus pembrolizumab is a standard first‐line therapy for advanced renal cell carcinoma (RCC), and acute acalculous cholecystitis is a rare adverse event. Case Presentation A 60‐year‐old woman with metastatic TFE3‐positive non–clear cell RCC, classified as poor risk by the International Metastatic RCC Database Consortium (IMDC) criteria, started pembrolizumab plus lenvatinib after palliative radiotherapy for cervical spine metastasis. Lenvatinib was initiated at 8 mg and escalated to 12 mg, achieving tumor shrinkage. Nine days after starting cycle 4, she developed fever and right upper quadrant pain. Computed tomography demonstrated gallbladder distension and wall thickening without gallstones, consistent with acute acalculous cholecystitis. Lenvatinib was interrupted, and intravenous piperacillin/tazobactam was administered; her symptoms improved without drainage. Lenvatinib was resumed at 8 mg with pembrolizumab, and no recurrence occurred.

Conclusion

Early recognition and temporary interruption of lenvatinib with antibiotics may allow cautious rechallenge.

Schlagwörter

Stichwörter der Autor:innen

acalculous cholecystitisadverse eventlenvatinibpembrolizumabrenal cell carcinoma

Autor:innen und Institutionen

  • Department of Urology Yokohama City University Graduate School of Medicine Yokohama Kanagawa Japan.

ORCID-Profile: Go Noguchi, Ryosuke Jikuya, Mitsuru Komeya, Hiroki Ito

Zitieren

APA

Soga, E., Noguchi, G., Kobayashi, K., Shibata, R., Jikuya, R., Tatenuma, T., Komeya, M., Ito, H., Hasumi, H., & Makiyama, K. (2026). A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma. IJU Case Reports, 9(4). https://doi.org/10.1002/iju5.70203

Vancouver

Soga E, Noguchi G, Kobayashi K, Shibata R, Jikuya R, Tatenuma T, et al. A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma. IJU Case Reports. 2026;9(4). doi:10.1002/iju5.70203

BibTeX
@article{Soga2026,
  author = {Soga, Erika and Noguchi, Go and Kobayashi, Kota and Shibata, Rio and Jikuya, Ryosuke and Tatenuma, Tomoyuki and Komeya, Mitsuru and Ito, Hiroki and Hasumi, Hisashi and Makiyama, Kazuhide},
  title = {A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {4},
  doi = {10.1002/iju5.70203}
}
Kostenlos starten →